Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

BOSTON & BASEL, Switzerland–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem firm, introduced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep studying expertise for antibody discovery and optimization. The staff and expertise stack will kind new bioinformatics and machine studying (ML) capabilities for Alloy and can be totally built-in into Alloy Discovery Services complementary workflow and processes. Alloy will develop the Basel deepCDR website as a everlasting Alloy analysis facility and will rent extra computational scientists and builders because it grows with the Alloy community.

The deepCDR engine combines deep sequencing and deep studying strategies with a proprietary mammalian show course of to choose from a variety of antibodies and quickly establish candidates with the very best potential affinity and developability profiles. The firm was a by-product of ETH Zurich and Department of Biosystems Science and Engineering and was based by Sai Reddy, an Associate Professor of Systems and Synthetic Immunology at ETH Zurich and an knowledgeable in immunogenomics and machine learning-guided protein engineering.

“Uniting deepCDR and Alloy displays our conviction within the energy of community results and scientific collaboration—collectively our corporations’ capabilities are amplified to higher serve the worldwide scientific group in its pursuit of discovering the perfect medicines for sufferers,” stated Alloy Therapeutics CEO and Founder Errik Anderson. “Our community of companions can be in a position to work with deepCDR’s machine studying engine in a method that in any other case would have been price prohibitive or inaccessible. The ongoing expertise enhancements will improve the output of Alloy platforms and Alloy Discovery Services for the good thing about all of our drug discovery companions.”

DeepCDR’s expertise will strengthen Alloy Discovery Services capabilities with patent-pending machine learning-powered antibody repertoire screening, in silico library screening, and mammalian show. DeepCDR thoughtfully integrates moist lab antibody screening and characterization with the computational instruments to allow a strong studying loop producing actual world outcomes. The deepCDR staff will kind Alloy’s new Basel, Switzerland operations and contains experience in antibody engineering and optimization, bioinformatics, and in silico library screening.

“We are thrilled to be part of Alloy on its mission of empowering scientific entrepreneurs and democratizing foundational drug discovery capabilities,” stated deepCDR founder Sai Reddy. “The knowledge units and infrastructure inside Alloy unlock highly effective new alternatives for the deepCDR expertise and staff that may in flip allow us to assist drug discovery groups extra successfully and effectively discover the perfect antibody candidates. We envision a future the place Alloy can be a pacesetter in unifying real-world affected person, genomic, and protein sequence knowledge to empower built-in AI and ML drug discovery and engineering.”

About Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem firm empowering the worldwide scientific group to make higher medicines collectively. Through a group of companions, Alloy democratizes entry to instruments, applied sciences, providers, and firm creation capabilities which can be foundational for locating and growing therapeutic biologics. The firm facilitates inexpensive, non-exclusive entry to your entire drug discovery group from educational scientists, small and medium biotech, to the biggest biopharma. Alloy’s lead providing, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a rising suite of proprietary transgenic mice strains. Alloy is a pacesetter in bispecific antibody discovery and engineering providers, using its proprietary ATX-CLC frequent gentle chain platform integrating novel transgenic mice and phage show. Alloy is headquartered in Boston, MA with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA. As a mirrored image of Alloy’s relentless dedication to the scientific group, Alloy reinvests 100% of its income in innovation and entry to innovation.

Join the Alloy Therapeutics group by visiting, following Alloy on LinkedIn, or scheduling a 15-minute chat with Alloy’s Founder and CEO at

Recommended For You